Search results for "replacement therapy"

showing 10 items of 289 documents

Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 func…

2015

AbstractBreast cancer is a heterogeneous disease and approximately 70% of newly diagnosed breast cancers are estrogen receptor (ER) positive. Out of the two ER types, α and β, ERα is the only ER that is detectable by immunohistochemistry in breast cancer biopsies and is the predominant subtype expressed in breast tumor tissue. ER-positive tumors are currently treated with anti-hormone therapy to inhibit ER signaling. It is well known that breast cancer cells can develop endocrine resistance and resistance to anti-hormone therapy and this can be facilitated via the autophagy pathway, but so far the description of a detailed autophagy expression profile of ER-positive cancer cells is missing.…

Cancer ResearchProgrammed cell deathImmunologyEstrogen receptorBreast NeoplasmsBiologyBAG3Cellular and Molecular NeuroscienceNeuroblastomaBreast cancermedicineAutophagyEstrogen Receptor betaHumansPrecision MedicineEstrogen receptor betaPI3K/AKT/mTOR pathwayAdaptor Proteins Signal TransducingEstrogen Replacement TherapyEstrogen Receptor alphaCell Biologymedicine.disease3. Good healthCell biologyGene Expression Regulation NeoplasticCancer cellMCF-7 CellsOriginal ArticleFemaleApoptosis Regulatory ProteinsEstrogen receptor alphaSignal TransductionCell Death & Disease
researchProduct

DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women

2019

Aim: Use of menopausal hormone therapy (MHT) has been associated with a reduced risk for colorectal cancer, but mechanisms underlying this relationship are not well understood. In the colon, MHT appears to act through estrogen receptor β (ERβ) which may influence DNA methylation by binding to DNA. Using genome-wide methylation profiling data, we aimed to identify genes that may be differentially methylated according to MHT use. Materials & methods: DNA methylation was measured using Illumina HumanMethylation450k arrays in two independent tumor sample sets of colorectal cancer patients. Differential methylation was determined using R/limma. Results: In the discovery analysis, two CpG si…

Cancer Researchmedicine.drug_classColorectal cancermedicine.medical_treatmentEstrogen receptorBiologychemistry.chemical_compoundGeneticsmedicineEstrogen Receptor betaHumansGeneAgedAged 80 and overEstrogen Replacement TherapyHormone replacement therapy (menopause)DNA MethylationMiddle Agedmedicine.diseasechemistryCpG siteEstrogenDNA methylationCancer researchCpG IslandsFemaleMenopauseColorectal NeoplasmsDNAEpigenomics
researchProduct

Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.

2006

Fabry disease is an X-linked lysosomal storage disorder characterized by multi-organ dysfunction, including hearing loss - mainly sensorineural. The recent introduction of enzyme replacement therapy (ERT) has resulted in improvements in renal and cardiac function, pain and quality of life. One study has also suggested small improvements in high-frequency hearing. In this paper, we study the effect of ERT on hearing in patients in the Europe-wide database - the Fabry Outcome Survey (FOS). Twenty-six patients in FOS had pure-tone audiometry performed up to 6 months before starting ERT with agalsidase alpha and after a median of 12 months of treatment. We assessed changes in hearing thresholds…

Cardiac function curveAdultMalemedicine.medical_specialtyHearing lossClinical BiochemistryAlpha (ethology)AudiologyBiochemistryQuality of lifeotorhinolaryngologic diseasesmedicineHumansLongitudinal Studiesmedicine.diagnostic_testbusiness.industryVascular diseaseGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryIsoenzymesTreatment OutcomeSensory Thresholdsalpha-GalactosidaseAudiometry Pure-ToneFabry DiseaseFemalemedicine.symptomAudiometrybusinessEuropean journal of clinical investigation
researchProduct

HERS study disturbs hormonal replacement therapy

2000

Cardiovascular protection of hormonal replacement therapy was considered a fact. The effects of estrogens on lipid levels and vascular health gave biological support to estrogen cardioprotection. The recently published HERS study showing no protective effects of estrogen and progesterone replacement therapy on the risk of myocardial infarction or coronary deaths is provoking perplexity. These surprising results may have several causes such as the use of progesterone, the associated use of cardioprotective agents or the short observation period. However, the study results scope is rectricted to secondary prevention. These cannot be extrapolated to frequent conditions of postmenopausal women …

CardioprotectionSecondary preventionmedicine.medical_specialtyPostmenopausal womenbusiness.industrymedicine.drug_classPhysiologyGeneral Medicinemedicine.diseaseVascular healthEndocrinologyCardiovascular diseasesHormone replacement therapyEstrogenInternal medicinePrimary preventionmedicineCardioprotective AgentMyocardial infarctionpost-menopausalEstrogen replacement therapybusiness
researchProduct

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal re…

2014

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus hepar…

Catheter Obstructionmedicine.medical_specialtyCatheterization Central VenousTime Factorsmedicine.medical_treatmentHemodialysis CatheterCatheter ObstructionMedicine (miscellaneous)urologic and male genital diseasesHospitals UniversityStudy ProtocolAcute renal failureClinical ProtocolsDouble-Blind MethodRenal DialysisCitrate lockIntensive careUpper Extremity Deep Vein ThrombosisProhibitinsmedicineCentral Venous CathetersHumansPharmacology (medical)Heparin lockRenal replacement therapyCitratesProspective StudiesContraindicationbusiness.industryHeparinAcute kidney injuryAnticoagulantsEquipment DesignAcute Kidney Injurymedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryCatheterIntensive Care UnitsTreatment OutcomeResearch DesignHemodialysisHemodialysisFranceCritically ill patientbusinessCatheter lockTrials
researchProduct

Anderson-Fabry Disease: A Multiorgan Disease

2013

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A . FD causes glycolipids, such as globotriaosylceramide (Gb3), to accumulate in the vascular endothelium of several organs (fig.2), including the skin, kidneys, nervous system, and heart, thereby triggering inflammation and fibrosis . These processes generally result in organ dysfunction, which is usually the first clinical evidence of FD. Patients with classic FD have various symptoms, eg, acroparesthesias, hypohidrosis, angiokeratomas, corneal opacities, cerebrovascular lesions, cardiac disorders, andrenal dysfunction.However, evolving knowledge about the natural course o…

Central Nervous SystemMalePathologymedicine.medical_specialtySettore MED/09 - Medicina InternaGlobotriaosylceramideDiseaseKidneySeverity of Illness IndexAnderson-Fabry disease multiorgan lysosomialNephropathychemistry.chemical_compoundDrug DiscoverymedicineHumansEnzyme Replacement TherapyEndothelial dysfunctionSkinPharmacologySex Characteristicsbusiness.industryOrgan dysfunctionAge FactorsKidney metabolismEnzyme replacement therapymedicine.diseaseFabry diseasechemistryQuality of LifeFabry DiseaseFemalemedicine.symptombusinessCurrent Pharmaceutical Design
researchProduct

CNS manifestations of Fabry's disease

2006

Summary Background Fabry's disease is a rare hereditary lysosomal storage disease with multiorgan involvement. Deficiency of α-galactosidase A activity leads to accumulation of neutral glycosphingolipids, especially in vascular endothelial and smooth-muscle cells. Along with progressive renal and cardiac dysfunction, stroke is a major and often life-threatening burden of the disease. Cerebral vasculopathy, confirmed by neuropathological, neuroradiological, and functional studies, occurs commonly and leads to ischaemic cerebrovascular events at an early age. Recent developments Fabry's disease is an X-linked disease and women have been regarded as only mildly affected carriers. However, rese…

Central Nervous SystemPediatricsmedicine.medical_specialtyPathologybusiness.industryBrainEnzyme replacement therapyDiseaseTransient ischaemic attacksmedicine.diseaseFabry's diseaseFabry diseaseStrokeCerebrovascular DisordersmedicineLysosomal storage diseaseFabry DiseaseHumansNeurology (clinical)Young adultbusinessStrokeThe Lancet Neurology
researchProduct

Transcranial Magnetic Stimulation Combined With Nicotine Replacement Therapy for Smoking Cessation: A Randomized Controlled Trial.

2015

Abstract Background Further evidence suggests that repetitive Transcranial Magnetic Stimulation (rTMS) is an effective method to reduce tobacco craving among smokers. Hypothesis As relapse is common within a few days after smoking cessation, we hypothesized that combining the anti-craving effects of rTMS with Nicotine replacement therapy (NRT) to attenuate withdrawal symptoms could increase abstinence rates in smokers with severe nicotine dependence who quit smoking. Methods Thirty-seven smokers who failed to quit with the usual treatments were randomly assigned to two treatment groups to receive either active ( n  = 18) or sham ( n  = 19) 1-Hz rTMS of the right dorsolateral prefrontal cort…

CessationAdultMaleNicotinemedicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectBiophysicsPrefrontal CortexCravingbehavioral disciplines and activitieslcsh:RC321-571law.inventionNicotineYoung AdultRandomized controlled triallawTobaccomental disordersmedicineHumansSingle-Blind MethodPsychiatrylcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymedia_commonCravingGeneral NeuroscienceTobacco Use DisorderAbstinenceMiddle AgedNicotine replacement therapyCombined Modality TherapyTranscranial Magnetic StimulationTobacco Use Cessation DevicesTranscranial magnetic stimulationTreatment Outcomenervous systemAnesthesiaCombinationbehavior and behavior mechanismsSmoking cessationFemaleSmoking CessationNeurology (clinical)medicine.symptomTobacco Use Cessation ProductsPsychologypsychological phenomena and processesmedicine.drugBrain stimulation
researchProduct

Ovarian tissue cryopreservation and transplantation in menopause: new perspective of therapy in postmenopausal women and the importance of ethical an…

2023

Menopausal transition entails a progressive decrease in hormone production by the ovaries that lead to important physical and psychological changes that could significantly affect quality of life. Hormone replacement therapy (HRT) administered from the onset of menopausal symptoms usually improves quality of life and life expectancy. Nevertheless, it is not risk-free. Ovarian tissue cryopreservation (OTC) has been investigated as a potential new strategy for delaying menopause and/or to avoid HRT. This review analyzes the critical points of HRT to assess whether OTC and subsequent reimplantation can affect postmenopausal management. We assessed available randomized clinical trials in PubMed…

CryopreservationCounselingTransplantationEstrogen Replacement TherapyEstrogensGuidelinesHormone replacement therapy (HRT)Settore MED/40 - Ginecologia E OstetriciaPostmenopauseOvarian tissue cryopreservation (OTC)Medicolegal viabilityQuality of LifeHumansOsteoporosisFemaleMenopause
researchProduct

Attenuated mucopolysaccharidosis: are you missing this debilitating condition?

2011

Diagnosis DifferentialRheumatologybusiness.industryMucopolysaccharidosisMedicineHumansPharmacology (medical)Enzyme Replacement TherapyMucopolysaccharidosesBioinformaticsbusinessmedicine.diseaseRheumatology (Oxford, England)
researchProduct